Document Detail


Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus.
MedLine Citation:
PMID:  21389264     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by a breakdown of tolerance to nuclear antigens and the development of immune complexes. Genomic approaches have shown that human SLE leukocytes homogeneously express type I interferon (IFN)-induced and neutrophil-related transcripts. Increased production and/or bioavailability of IFN-α and associated alterations in dendritic cell (DC) homeostasis have been linked to lupus pathogenesis. Although neutrophils have long been shown to be associated with lupus, their potential role in disease pathogenesis remains elusive. Here, we show that mature SLE neutrophils are primed in vivo by type I IFN and die upon exposure to SLE-derived anti-ribonucleoprotein antibodies, releasing neutrophil extracellular traps (NETs). SLE NETs contain DNA as well as large amounts of LL37 and HMGB1, neutrophil proteins that facilitate the uptake and recognition of mammalian DNA by plasmacytoid DCs (pDCs). Indeed, SLE NETs activate pDCs to produce high levels of IFN-α in a DNA- and TLR9 (Toll-like receptor 9)-dependent manner. Our results reveal an unsuspected role for neutrophils in SLE pathogenesis and identify a novel link between nucleic acid-recognizing antibodies and type I IFN production in this disease.
Authors:
Gina S Garcia-Romo; Simone Caielli; Barbara Vega; John Connolly; Florence Allantaz; Zhaohui Xu; Marilynn Punaro; Jeanine Baisch; Cristiana Guiducci; Robert L Coffman; Franck J Barrat; Jacques Banchereau; Virginia Pascual
Related Documents :
21320644 - The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthri...
1842804 - Humoral immune response of normal rhesus monkeys during primaquine administration.
21238904 - Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstru...
10977954 - Role of corticosterone in realization of immunosuppressive effects in acute poisoning w...
19665984 - Pro-apoptotic effects of antimalarial drugs do not affect mature human erythrocytes.
10413194 - Use of immunotoxicity data in health risk assessments: uncertainties and research to im...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Science translational medicine     Volume:  3     ISSN:  1946-6242     ISO Abbreviation:  Sci Transl Med     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-10     Completed Date:  2011-07-06     Revised Date:  2012-03-12    
Medline Journal Info:
Nlm Unique ID:  101505086     Medline TA:  Sci Transl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  73ra20     Citation Subset:  IM    
Affiliation:
Baylor Institute for Immunology Research, Dallas, TX 752014, USA.
Data Bank Information
Bank Name/Acc. No.:
GEO/GSE27427
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antibodies, Antinuclear / blood
Apoptosis / immunology
Autoantibodies / blood
Case-Control Studies
Child
Dendritic Cells / immunology
Gene Expression Profiling
Humans
Interferon Type I / biosynthesis*
Lupus Erythematosus, Systemic / blood,  genetics,  immunology*
NADP / blood
Neutrophils / immunology*,  pathology
Oligonucleotide Array Sequence Analysis
Receptors, IgG / blood
Ribonucleoproteins / immunology
Toll-Like Receptor 7 / blood
Grant Support
ID/Acronym/Agency:
AR054083-01/AR/NIAMS NIH HHS; ARO55503-01//PHS HHS; P50 AR054083-01/AR/NIAMS NIH HHS; P50 AR054083-02/AR/NIAMS NIH HHS; P50 AR054083-03/AR/NIAMS NIH HHS; P50 AR054083-04/AR/NIAMS NIH HHS; P50 AR054083-04S1/AR/NIAMS NIH HHS; P50 AR054083-05/AR/NIAMS NIH HHS; R01 AR050770-01/AR/NIAMS NIH HHS; R01 AR050770-01/AR/NIAMS NIH HHS; R01 AR050770-02/AR/NIAMS NIH HHS; R01 AR050770-03/AR/NIAMS NIH HHS; R01 AR050770-04/AR/NIAMS NIH HHS; R01 AR050770-05A1/AR/NIAMS NIH HHS; R01 AR050770-06/AR/NIAMS NIH HHS; R01 AR050770-07/AR/NIAMS NIH HHS; R01 AR050770-08/AR/NIAMS NIH HHS; R01 CA078846-01A1/CA/NCI NIH HHS; R01 CA078846-02/CA/NCI NIH HHS; R01 CA078846-03/CA/NCI NIH HHS; R01 CA078846-04/CA/NCI NIH HHS; R01 CA078846-05/CA/NCI NIH HHS; R01 CA078846-06/CA/NCI NIH HHS; R01 CA078846-07/CA/NCI NIH HHS; R01 CA078846-08/CA/NCI NIH HHS; R01 CA078846-09/CA/NCI NIH HHS; R01 CA078846-10/CA/NCI NIH HHS; R01-CA078846/CA/NCI NIH HHS; U19 AI057234-01/AI/NIAID NIH HHS; U19 AI057234-02/AI/NIAID NIH HHS; U19 AI057234-03/AI/NIAID NIH HHS; U19 AI057234-04/AI/NIAID NIH HHS; U19 AI057234-05/AI/NIAID NIH HHS; U19 AI057234-05S1/AI/NIAID NIH HHS; U19 AI057234-06/AI/NIAID NIH HHS; U19 AI057234-06S1/AI/NIAID NIH HHS; U19 AI057234-06S2/AI/NIAID NIH HHS; U19 AI057234-06S3/AI/NIAID NIH HHS; U19 AI057234-07/AI/NIAID NIH HHS; U19 AI057234-07S1/AI/NIAID NIH HHS; U19 AI057234-08/AI/NIAID NIH HHS; U19 AI057234-09/AI/NIAID NIH HHS; U19 AI082715-01/AI/NIAID NIH HHS; U19 AI082715-02/AI/NIAID NIH HHS; U19 AI082715-03/AI/NIAID NIH HHS; U19 AI082715-04/AI/NIAID NIH HHS; U19-A1057234//PHS HHS; U19-AI082715-01/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Antinuclear; 0/Autoantibodies; 0/Fc gamma receptor IIA; 0/Interferon Type I; 0/Receptors, IgG; 0/Ribonucleoproteins; 0/TLR7 protein, human; 0/Toll-Like Receptor 7; 53-59-8/NADP
Comments/Corrections
Comment In:
EMBO Mol Med. 2011 Oct;3(10):578-80   [PMID:  21905225 ]
Sci Transl Med. 2011 Mar 9;3(73):73ps9   [PMID:  21389262 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemi...
Next Document:  Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment.